A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2014 May 21

PMID 24841203

Citations 31

Authors

Juergen M Schanzer

Katharina Wartha

Rebecca Croasdale

Samuel Moser

Klaus-Peter Kunkele

Carola Ries

Werner Scheuer

Harald Duerr

Sandra Pompiati

Jan Pollman

Jan Stracke

Wilma Lau

Stefan Ries

Ulrich Brinkmann

Christian Klein

Pablo Umana

Affiliations

Soon will be listed here.

Abstract

In the present study, we have developed a novel one-arm single chain Fab heterodimeric bispecific IgG (OAscFab-IgG) antibody format targeting the insulin-like growth factor receptor type I (IGF-1R) and the epidermal growth factor receptor (EGFR) with one binding site for each target antigen. The bispecific antibody XGFR is based on the "knob-into-hole" technology for heavy chain heterodimerization with one heavy chain consisting of a single chain Fab to prevent wrong pairing of light chains. XGFR was produced with high expression yields and showed simultaneous binding to IGF-1R and EGFR with high affinity. Due to monovalent binding of XGFR to IGF-1R, IGF-1R internalization was strongly reduced compared with the bivalent parental antibody, leading to enhanced Fc-mediated cellular cytotoxicity. To further increase immune effector functions triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted in strong antibody-dependent cell-mediated cytotoxicity activity. XGFR-mediated inhibition of IGF-1R and EGFR phosphorylation as well as A549 tumor cell proliferation was highly effective and was comparable with a combined treatment with EGFR (GA201) and IGF-1R (R1507) antibodies. XGFR also demonstrated potent anti-tumor efficacy in multiple mouse xenograft tumor models with a complete growth inhibition of AsPC1 human pancreatic tumors and improved survival of SCID beige mice carrying A549 human lung tumors compared with treatment with antibodies targeting either IGF-1R or EGFR. In summary, we have applied rational antibody engineering technology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inhibition with antibody-dependent cell-mediated cytotoxicity induction and results in superior molecular properties over two established tetravalent bispecific formats.

Citing Articles

From Cell Clones to Recombinant Protein Product Heterogeneity in Chinese Hamster Ovary Cell Systems.

Wang C, Guo X, Wang W, Li J, Wang T Int J Mol Sci. 2025; 26(3).

PMID: 39941092 PMC: 11818180. DOI: 10.3390/ijms26031324.

Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform.

Liu P, Gu C, Cao X, Zhang H, Wang Z, Yang Y Antib Ther. 2025; 8(1):1-12.

PMID: 39839911 PMC: 11744305. DOI: 10.1093/abt/tbae027.

Design and engineering of bispecific antibodies: insights and practical considerations.

Madsen A, Pedersen L, Kristensen P, Goletz S Front Bioeng Biotechnol. 2024; 12:1352014.

PMID: 38333084 PMC: 10850309. DOI: 10.3389/fbioe.2024.1352014.

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.

Loh H, Bin Mahfut F, Chen S, Huang Y, Huo J, Zhang W MAbs. 2023; 15(1):2231129.

PMID: 37403264 PMC: 10324450. DOI: 10.1080/19420862.2023.2231129.

The renaissance of chemically generated bispecific antibodies.

Szijj P, Chudasama V Nat Rev Chem. 2023; 5(2):78-92.

PMID: 37117612 DOI: 10.1038/s41570-020-00241-6.

References

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M . A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012; 7(2):419-26. PMC: 3358820. DOI: 10.1097/JTO.0b013e31823c5b11. View

Kontermann R, Wing M, Winter G . Complement recruitment using bispecific diabodies. Nat Biotechnol. 1997; 15(7):629-31. DOI: 10.1038/nbt0797-629. View

Pollak M . Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-28. DOI: 10.1038/nrc2536. View

Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Matsubara O . Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Sci. 2006; 97(7):597-604. PMC: 11158992. DOI: 10.1111/j.1349-7006.2006.00228.x. View

Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M . A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005; 280(20):19665-72. DOI: 10.1074/jbc.M500815200. View

DiGiammarino E, Harlan J, Walter K, Ladror U, Edalji R, Hutchins C . Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs. 2011; 3(5):487-94. PMC: 3225853. DOI: 10.4161/mabs.3.5.16326. View

Surati M, Patel P, Peterson A, Salgia R . Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011; 11(12):1655-62. PMC: 3258451. DOI: 10.1517/14712598.2011.626762. View

Schirrmann T, Menzel C, Hust M, Prilop J, Jostock T, Dubel S . Oligomeric forms of single chain immunoglobulin (scIgG). MAbs. 2010; 2(1):73-6. PMC: 2828580. DOI: 10.4161/mabs.2.1.10784. View

Dong J, Sereno A, Snyder W, Miller B, Tamraz S, Doern A . Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem. 2010; 286(6):4703-17. PMC: 3039382. DOI: 10.1074/jbc.M110.184317. View

10.

Baselga J, Mendelsohn J . The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994; 29(1):127-38. DOI: 10.1007/BF00666188. View

11.

Michaelson J, Demarest S, Miller B, Amatucci A, Snyder W, Wu X . Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs. 2010; 1(2):128-41. PMC: 2725416. DOI: 10.4161/mabs.1.2.7631. View

12.

Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen R, Valerie K . The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001; 20(11):1388-97. DOI: 10.1038/sj.onc.1204255. View

13.

Paz-Ares L, Gomez-Roca C, Delord J, Cervantes A, Markman B, Corral J . Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol. 2011; 29(28):3783-90. DOI: 10.1200/JCO.2011.34.8888. View

14.

Ramalingam S, Spigel D, Chen D, Steins M, Engelman J, Schneider C . Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2011; 29(34):4574-80. PMC: 5320944. DOI: 10.1200/JCO.2011.36.6799. View

15.

Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A . Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007; 25(11):1290-7. DOI: 10.1038/nbt1345. View

16.

Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M . Single chain Fab (scFab) fragment. BMC Biotechnol. 2007; 7:14. PMC: 1829395. DOI: 10.1186/1472-6750-7-14. View

17.

Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A . High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009; 20(5):842-9. DOI: 10.1093/annonc/mdn727. View

18.

Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I . Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011; 108(31):12669-74. PMC: 3150898. DOI: 10.1073/pnas.1108455108. View

19.

Chakravarti A, Loeffler J, Dyson N . Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1):200-7. View

20.

Reiter Y, Brinkmann U, Kreitman R, Jung S, Lee B, Pastan I . Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 1994; 33(18):5451-9. DOI: 10.1021/bi00184a014. View